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Background: Classical and delayed preconditioning are powerful endogenous protection mechanisms against
ischemia-reperfusion damage. However, it is still uncertain whether delayed preconditioning can effectively salvage
myocardium in patients with co-morbidities, such as diabetes and the metabolic syndrome. We investigated
delayed preconditioning in mice models of type II diabetes and the metabolic syndrome and investigated
interventions to optimize the preconditioning potential.
Methods: Hypoxic preconditioning was induced in C57Bl6-mice (WT), leptin deficient ob/ob (model for type II
diabetes) and double knock-out (DKO) mice with combined leptin and LDL-receptor deficiency (model for
metabolic syndrome). Twenty-four hours later, 30 min of regional ischemia was followed by 60 min reperfusion.
Left ventricular contractility and infarct size were studied. The effect of 12 weeks food restriction or angiotensin-
converting enzyme inhibition (ACE-I) on this was investigated. Differences between groups were analyzed for
statistical significance by student’s t-test or one-way ANOVA followed by a Fisher’s LSD post hoc test. Factorial
ANOVA was used to determine the interaction term between preconditioning and treatments, followed by a
Fisher’s LSD post hoc test. Two-way ANOVA was used to determine the relationship between infarct size and
contractility (PRSW). A value of p<0.05 was considered significant.
Results: Left ventricular contractility is reduced in ob/ob compared with WT and even further reduced in DKO.
ACE-I improved contractility in ob/ob and DKO mice. After ischemia/reperfusion without preconditioning, infarct
size was larger in DKO and ob/ob versus WT. Hypoxic preconditioning induced a strong protection in WT and a
partial protection in ob/ob mice. The preconditioning potential was lost in DKO. Twelve weeks of food restriction or
ACE-I restored the preconditioning potential in DKO and improved it in ob/ob.
Conclusion: Delayed preconditioning is restored by food restriction and ACE-I in case of type II diabetes and the
metabolic syndrome.
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Tissues and organs can be protected from ensuing
longer ischemia-reperfusion (IR) periods by short pre-
ceding episodes of ‘preconditioning’ ischemia [1]. How-
ever, after 26 years of research and the consistent and
significant protection of cardiac preconditioning found
in most experimental studies, none of these results has
been translated into clinical therapies [1-5]. There are
several reasons. The stimulus to induce preconditioning,
such as repeated temporary coronary occlusion or aortic
cross-clamping, can be harmful itself and prolongs the
procedure. It was further debated whether standard
maneuvers, such as cardiopulmonary bypass during car-
diac surgery, themselves precondition the patient [4]. An-
other important issue in this failure, is the uncertainty
whether this technique can effectively salvage myocardium
in patients with co-morbidities, such as type 2 diabetes
(T2D) or the metabolic syndrome (MS), that are frequent
in the intended patient population [1,5].
The number of patients with diabetes and the metabolic
syndrome increases in Western societies and reaches epi-
demic proportions [6-9]. The incidence of myocardial in-
farction is twice that of the general population and infarct
size, for a given ischemic insult, is larger [7,8]. Large-scale
clinical trials showed that intensive glycemic control failed
to reduce cardiovascular mortality and macrovascular
incidents including myocardial infarction, in comparison
with standard glucose control in diabetic patients [9].
Therefore, new or additional techniques to protect the dia-
betic heart against ischemic damage are eagerly awaited.
Delayed preconditioning might be an interesting tech-
nique for this, since it is capable to induce cardioprotection
in a controlled way for longer periods. Most of our know-
ledge concerning preconditioning however has been
gathered from experiments in normal healthy animal
models [1]. These models are not optimal to study precon-
ditioning for the clinical population that might benefit
most of it, i.e. patients with T2D or the MS. Delayed
preconditioning reduces infarct size and preserves cardiac
contractility in wild type (WT)-mice after ischemia-
reperfusion [10], but not in models of type I diabetes [11].
Clinical studies report that type II diabetic myocardium is
resistant or has a higher threshold to classical precon-
ditioning [2,3]. The effect of delayed preconditioning on
cardiac IR in mouse models of T2D and the MS has never
been investigated and is the focus of this study.
Most patients with T2D or the MS are treated [12].
These treatments might additionally influence the precon-
ditioning potential. Despite the fact that hypocaloric diet
is a standard treatment in T2D and the MS [12], its car-
diovascular effects are incompletely understood. A study
with obese rats showed that food restriction partially
restores classical preconditioning [13]. The effects of long-
term food restriction on delayed preconditioning wasnever investigated. Food restriction increases endothelial
nitric oxide synthase (eNOS)-levels in a mouse model of
the metabolic syndrome [14], NO being a determinant
trigger in the delayed preconditioning pathway [1]. It is
therefore conceivable that food restriction restores the
delayed preconditioning potential and induces cardiopro-
tection by this mechanism.
Angiotensin-converting enzyme inhibition (ACE-I) is
also a standard therapy in the treatment of hypertension in
diabetic patients [12]. It was previously shown that ACE-I
is capable to augment classical [15,16] and delayed pre-
conditioning [17,18] in WT animal models, by lowering
the stimulus threshold. There are no data concerning the
effect of ACE-I on the delayed preconditioning in T2D and
MS models. ACE-I might however impact on the delayed
preconditioning potential since it is capable to block the
degradation of bradykinin into inactive peptides and to in-
crease eNOS and nitric oxide (NO)-levels [15,16,19].
Therefore, the aim of this study is to investigate the
effects of food restriction and ACE-I on delayed cardiac
preconditioning in diabetic or metabolic syndrome models.
We tested the hypotheses that 1° mice with T2D or the MS
are resistant to hypoxic delayed preconditioning; and 2° the
interventions food restriction or ACE-I restore the pre-
conditioning potential in these mouse models.
Methods and materials
Animal models
Experiments were conducted in 49 C57BL/6J WT-mice, 71
leptin deficient ob/ob, and 68 double knock-out (DKO)-
mice with combined leptin and LDL-receptor deficiency.
The ob/ob mouse is a model for T2D, featuring abdominal
obesity and insulin resistance. DKO feature many charac-
teristics of the metabolic syndrome, i.e. obesity, dysli-
pidemia, hypertension, insulin resistance and impaired
glucose tolerance and/or diabetes [14]. These models de-
velop left ventricular diastolic and systolic dysfunction
comparable with the diabetic cardiomyopathy seen in
patients [20]. Ob/ob and C57BL/6J-mice were purchased
from Jackson Laboratory (Bar Harbor, Maine, USA). DKO
were generated as described previously [14,20]. IR was
induced at 24 weeks of age. The investigation conforms
with the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health
(NIH Publication 1996). All experimental protocols were
approved by the K.U. Leuven Institutional Animal Care
Commission and Ethical Committee.
Delayed preconditioning stimulus
The experimental technique was previously described
[10]. Briefly, mice were placed in a plexiglas container, in
which controlled oxygen levels of 6% could be induced
within 30 seconds using a mixture of nitrogen and
compressed air. Five cycles of 6 minutes of 6% oxygen,
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non-preconditioned groups, only compressed air was used
without nitrogen. Afterwards, mice were placed in their
regular cage with food and water ad libitum for 24 hours.
Treatments
Food intake (Ssniff, Soest, Germany) of diet-restricted ob/
ob (n=7 sham, n=9 non-preconditioned, n=8 precon-
ditioned) and DKO (n=7 sham, n=7 non-preconditioned,
n=8 preconditioned) mice was restricted to 2.5 g/day,
which is the normal daily intake of lean WT-mice, be-
tween 12 and 24 weeks of age [14,21]. ACE-inhibition was
obtained with captopril (10 mg/kg/day) intraperitoneally
from 12 until 24 weeks of age in WT (n=6 sham, n=7
non-preconditioned, n=8 preconditioned), ob/ob (n=7
sham, n=9 non-preconditioned, n=8 preconditioned) and
DKO (n=7 sham, n=9 non-preconditioned, n=8 precon-
ditioned) [22].
Experiments in untreated WT (n=8 sham, n=11 non-
preconditioned, n=9 preconditioned), ob/ob (n=6 sham,
n=9 non-preconditioned, n=8 preconditioned) and DKO
(n=7 sham, n=7 non-preconditioned, n=8 preconditioned)
mice served as controls.
Ischemia/reperfusion
The experimental technique was previously described
[10,20]. Briefly, anesthesia was induced with urethane (1.2
g/kg) and alfa-chloralose (50 mg/kg). Mice were ventilated
with room air, with rectal temperature kept at 37±0.5°C.
Via left thoracotomy, the left anterior descending artery
(LAD), was non-traumatically occluded, 2 mm below the
tip of the left auricle for 30 min. Afterwards, a reperfusion
period of 1 hour was allowed. Successful coronary occlu-
sion and reperfusion was visually verified by observing the
myocardium distal to the coronary occlusion turning pale
respectively blushing. In the groups without ischemia
(sham), a thoracotomy and time-matched procedure was
performed.
Outcome parameters: infarct size and in vivo left
ventricular contractility
The technique was previously described [10,20]. At the
end of 1 hour reperfusion, a pressure-conductance cath-
eter (1.4-Fr, SPR-839; Millar Instruments, Houston, TX)
was inserted through the right carotid artery into the left
ventricle. Baseline pressure-volume (PV) loops were
recorded (Powerlab/ADInstruments, Castle Hill, Australia).
Parallel volume and specific blood conductance were
determined [10,20,21]. The inferior caval vein was com-
pressed to obtain left ventricular PV-loops under varying
loading conditions. Heart rate, systolic and end-diastolic
pressure were measured. Stroke volume was determined as
the difference in end-diastolic and end-systolic volume.
Stroke work (SW) is the mechanical energy which theheart develops during the cardiac cycle and is calculated as
the area enclosed by the PV-loop.
Preload recruitable stroke work (PRSW) is the slope of
the relationship between end-diastolic volume and SW
performed by the ventricle. PRSW is the most reliable
and useful parameter for general contractility since it is
chamber size independent and robust [23]. The slope of
the end-systolic pressure-volume relationship, end-
systolic elastance (Ees), reflects left ventricular chamber
end-systolic stiffness and is used as an index of contract-
ility. Tau is the time constant of left ventricular relax-
ation during isovolumetric diastole. The end-diastolic
PV-relationship (EDPVR) represents the compliance of
the ventricular myocardium at the end of the diastole.
Augmented stiffness of the ventricular wall increases the
slope of the EDPVR. Arterial elastance (Ea), a measure
for afterload, is defined as the end-systolic pressure to
stroke volume ratio [23].
Before excision of the heart, Evans blue (0.8 ml, 1% so-
lution) was injected intravenously after re-occlusion of
the LAD, to determine the left ventricular perfusion area
at risk. The heart was cut in 1 mm-slices and the slices
were stained with triphenyl-tetrazolium-chloride solu-
tion (TTC, 20 min, 1%, 37°C, pH 7.4) and fixed in
paraformaldehyde (10 min, 4% solution, 20°C). All slices
were weighed and photographed with a digital camera
under magnification.
Data management and statistical analysis
Analysis of the pressure-conductance data was performed
using PVAN 3.2 software (Millar Instruments, Houston)
as previously described [10,20,21,23].
Infarct size and area at risk were determined by the
number of pixels in each zone with Adobe Photoshop
8.0 (Adobe System Inc.) multiplied by the weight of the
respective slices.
All statistical analyses were performed using statistical
software (Statistica 7.1, StatSoft, Tulsa, USA). Data are
expressed as mean ± standard deviation. Differences be-
tween groups were analyzed for statistical significance by
student’s t-test or one-way ANOVA followed by a Fisher’s
LSD post hoc test. Factorial ANOVA was used to deter-
mine the interaction term between preconditioning and
treatments, followed by a Fisher’s LSD post hoc test. Two-
way ANOVA was used to determine the relationship be-
tween infarct size and contractility (PRSW). A value of
p<0.05 was considered significant.
Results
Effect of preconditioning in untreated mice
Preconditioning without subsequent ischemia, was in-
vestigated in WT (n=8 sham preconditioned; n=8 sham
non-preconditioned) and DKO (n=7 sham preconditioned;
n=7 sham non-preconditioned) mice. As expected, this
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can be found in Additional file 1.
Left ventricular contractility, expressed as PRSW
(Figure 1), is reduced in ob/ob compared with WT and
even further reduced in DKO (Table 1). The area at risk
after coronary occlusion is comparable in all groups
undergoing IR. After IR without preconditioning, in-
farct size was larger in DKO (Table 2) and ob/ob versus
WT (Figure 2). IR impaired PRSW significantly in all
groups, but to a significantly lower level in DKO and
ob/ob than in WT (Table 1).
Preconditioning induced a strong protection in WT
mice. Infarct size, stroke volume, Ees, Ea and PRSW were
significantly better preserved after preconditioning (Table 1,
2 and Additional file 2). In ob/ob, delayed preconditioning
failed to significantly reduce infarct size (p = 0.06).
Nevertheless, load-independent left ventricular contractil-
ity, as measured by PRSW, was better preserved afterFigure 1 Preload recruitable stroke work in wild type, ob/ob
and double knock-out mice. White bar: Non ischemic (sham);
Black bar: Non-preconditioned and IR injury; Dashed bar:
Preconditioned and IR injury“a” p<0.05 versus WT same treatment,
same condition (sham; non-preconditioned; preconditioned); “b”
p<0.05 versus same untreated genotype, same condition; “c” p<0.05
versus sham, same genotype, same treatment; “d” p<0.05 versus non-
preconditioned, same genotype, same treatment; “e” p<0.05 versus
diet, same genotype, same condition; “f” p<0.05 versus ob/ob same
treatment, same condition.preconditioning. The preconditioning potential was lost in
DKO mice: infarct size was not reduced and none of the
contractility parameters were significantly better preserved
after preconditioning. The relationship between infarct
limitation and improved contractility was significantly dif-
ferent in DKO and WT mice. In DKO, preconditioning
induced a proportional smaller improved PRSW per
reduced infarct area versus WT mice (Additional file 3).Effect of food restriction on preconditioning
Food restriction did not improve the reduced PRSW in
sham ob/ob and DKO mice (Figure 1). Food restriction
did not influence infarct size and PRSW in non-
preconditioned DKO and ob/ob versus the untreated
groups (Table 1 and 2) [10].
After food restriction, delayed preconditioning was
restored in ob/ob mice, as seen by the significantly
reduced infarct size, and significantly better preserved
Ees and PRSW. These load-independent contractility
parameters reached values comparable to the non-
ischemic sham group.
Furthermore, food restriction restored the precon-
ditioning potential in DKO mice: infarct size and PRSW
were significantly better preserved versus the non-
preconditioned group. Left ventricular contractility,
expressed as PRSW, remained worse versus food
restricted and preconditioned ob/ob mice.Effect of ACE-I on preconditioning
ACE-I improved contractility in sham ob/ob and DKO
mice, not in WT. Furthermore, PRSW was significantly
better after 12 weeks of ACE-I in ob/ob and DKO versus
diet (Figure 1). Without preconditioning, ACE-I did not
reduce infarct size and the impact of IR injury on PRSW
in any genotype versus the untreated groups (Table 1
and 2) [10].
After ACE-I treatment, the protective effect of precon-
ditioning on PRSW and SW was increased in WT-mice
versus the untreated group (Table 1 and Additional file 2).
After ACE-I treatment, delayed preconditioning was
fully restored in ob/ob mice concerning stroke work,
Tau, Ees and PRSW. Infarct size after preconditioning
was even smaller than the already beneficial effect that
could be obtained with diet (Figure 2).
Also in DKO mice, ACE-I treatment restored delayed
preconditioning. Infarct size and PRSW were significantly
better preserved than the non-preconditioned group. After
ACE-I treatment and preconditioning in DKO mice,
PRSW was better preserved versus food restricted precon-
ditioned DKO and reached the level of the sham group
without ischemia. After ACE-I and preconditioning, the
proportional effect on infarct limitation and improved con-
tractility was restored to the WT-level (Additional file 3).
Table 1 Load-independent hemodynamic parameters
Wild type Ob/ob DKO
Condition Sham NP P Sham NP P Sham NP P
PRSW (mmHg) Untreated 87.9±5.0 60.2±11.8c 76.3±5.4 cd 64.5±2.5 a 48.1±3.6 ac 57.1±5.2 acd 58.0±4.1 af 48.6±6.5 ac 49.2±3.0 acf
Diet 65.8±1.7 50.4±1.0 c 64.4±3.1 bd 58.2±3.0 f 49.5±3.2 c 55.9±3.5 bdf
ACE-I 88.0±4.6 59.3±6.8 c 81.2±3.1 bcd 72.4±3.1 abe 52.3±3.6 ac 69.8±2.9 abde 65.9±5.3 abef 51.1±3.6 ac 63.9±3.3 abdef
Ees (mmHg/μl) Untreated 8.3±2.5 6.4±1.5 8.5±1.7 d 5.0±0.4 a 4.8±1.7 5.6±1.2 a 6.0±2.2 4.5±0.8 a 4.8±2.3 a
Diet 6.3±2.2 4.4±1.2 7.3±2.2d 5.1±1.3 5.4±1.2 5.6±1.1
ACE-I 6.0±1.1 6.2±1.6 8.7±1.7 cd 5.3±1.7 4.2±1.3 6.4±1.6 ad 5.6±1.4 4.3±1.4 5.2±3.0 a
EDPVR (mmHg/μl) Untreated 0.2±0.2 0.4±0.2 0.3±0.2 0.4±0.3 0.4±0.3 0.5±0.3 a 0.5±0.4 0.3±0.1 0.3±0.2
Diet 0.3±0.2 0.2±0.1 0.2±0.1 b 0.3±0.1 0.2±0.1 b 0.3±0.2
ACE-I 0.2±0.2 0.4±0.4 0.2±0.1 0.4±0.1 0.3±0.1 0.3±0.1 bc 0.3±0.1 f 0.3±0.1 0.2±0.1
ACE-I: angiotensin-converting enzyme inhibition; DKO: double knock-out (ob/ob; LDLR-/-); EDPVR: end-diastolic pressure-volume relationship; Ees: end-systolic
elastance; IR: ischemia/reperfusion; NP: Non-Preconditioned and ischemia/reperfusion; P: Preconditioned and ischemia/reperfusion; PRSW: preload recruitable
stroke work; sham: group without ischemia/reperfusion. “a” p<0.05 versus WT same treatment, same condition (sham; non-preconditioned; preconditioned);
“b” p<0.05 versus same untreated genotype, same condition; “c” p<0.05 versus sham, same genotype, same treatment; “d” p<0.05 versus non-preconditioned,
same genotype, same treatment; “e” p<0.05 versus diet, same genotype, same condition; “f” p<0.05 versus ob/ob same treatment, same condition.
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Hypoxic preconditioning was capable to induce a strong
protection in WT mice, but not in the DKO model of MS.
Furthermore, the relationship between infarct limitation
and improved contractility after preconditioning was dif-
ferent in DKO than in WT mice. In DKO, preconditioning
induced a proportionally smaller improved PRSW per
reduced infarct area versus WT mice. In ob/ob, precon-
ditioning induced only a partial preservation of left ven-
tricular contractility. The degree of protection was inferior
to that in WT.
Since we have not directly investigated the mechanisms
underlying the reduced or abolished delayed precon-
ditioning potential, we can only hypothesize on them. ThisTable 2 Numbers and infarct size
Wild type
Condition Sham NP P
N experiments (survivors) Untreated 8 (8) 11 (9) 9 (9)
Diet
ACE-I 6 (6) 7 (6) 8 (8)
Weight (g) Untreated 28.3±4.6
Diet
ACE-I 27.1±3.4
Area at risk (% of heart) Untreated 0 15.4±7.6 c 16.6±6.9 c
Diet
ACE-I 0 19.0±5.8 c 18.8±7.4 c
Infarct size (% of area at risk) Untreated 0 50.2±6.5 c 28.9±12.3 cd
Diet
ACE-I 0 53.2±3.5 c 23.6±6.1 cd
ACE-I: angiotensin-converting enzyme inhibition; DKO: double knock-out (ob/ob; LD
reperfusion and Preconditioned. “a” p<0.05 versus WT same treatment, same condit
untreated genotype, same condition; “c” p<0.05 versus sham, same genotype, same
treatment; “e” p<0.05 versus diet, same genotype, same condition.should further be investigated in depth to allow specific,
additional therapeutic interventions. Potential underlying
mechanisms are numerous.
First, our models are known with raised concentrations
of non-esterified fatty acids, insulin resistance and hyper-
glycemia [14,20,21]. These metabolic anomalies induce
atypical isoforms of protein-kinase C [24], which is crucial
in the pathway of delayed preconditioning [1].
Second, insulin induces a preconditioning effect [5]. It
was shown that at 24 weeks, both ob/ob and DKO mice
have increased insulin levels [14,20]. It is therefore pos-
sible that mouse models with hyperinsulinemia are in a
permanent preconditioned state or require a higher
threshold to preconditioning [5,25].Ob/ob DKO
Sham NP P Sham NP P
6 (6) 9 (6) 8 (7) 7 (6) 7 (6) 8 (7)
7 (6) 9 (6) 8 (7) 7 (6) 7 (7) 8 (8)
7 (7) 9 (7) 8 (7) 7 (7) 9 (7) 8 (7)
62.4±3.8 a 59.1±9.5 a
38.3±4.7 b 37.9±3.4 b
62.9±9.4 ae 63.6±8.5 ae
0 15.6±6.1c 12.4±5.5 c 0 18.8±7.6 c 12.9±3.5 c
0 18.7±2.6 c 19.4±6.6 c 0 17.5±8.7 c 17.9±10.7 c
0 16.4±3.0 c 17.5±8.8 c 0 14.4±5.3 c 16.1±7.1 c
0 72.7±8.0 ac 62.9±7.8 ac 0 67.4±6.6 ac 65.1±7.1 ac
0 66.8±9.7 c 56.5±6.4 cd 0 71.2±12.3 c 57.7±7.6 cd
0 69.6±8.6 ac 49.7±5.5 abcde 0 66.4±7.8 ac 53.3±10.4 abcd
LR-/-); NP: ischemia/reperfusion and Non-Preconditioned; P: ischemia/
ion (sham; non-preconditioned; preconditioned); “b” p<0.05 versus same
treatment; “d” p<0.05 versus non-preconditioned, same genotype, same
Figure 2 Infarct size as % of risk zone in wild type, ob/ob and
double knock-out mice. Black bar: Non-preconditioned and IR
injury; Dashed bar: Preconditioned and IR injury “a” p<0.05 versus WT
same treatment, same condition (sham; non-preconditioned;
preconditioned); “b” p<0.05 versus same untreated genotype, same
condition; “c” p<0.05 versus sham, same genotype, same treatment;
“d” p<0.05 versus non preconditioned, same genotype, same
treatment; “e” p<0.05 versus diet, same genotype, same condition.
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mitochondrial reactive oxygen species (ROS), generated in
response to a preconditioning stimulus [1,2]. Increased
oxidative stress is demonstrated in our mouse models
[14,20]. It is therefore possible that increased ROS-levels
induce a permanent preconditioned state or induce a
higher threshold to preconditioning.
Fourth, the role of NO in IR injury and preconditioning
is complex and depends on its concentration and cellular
origin [1,26]. eNOS is a trigger in the delayed precon-
ditioning pathway. Endothelial dysfunction and reduced
nitric oxide (NO) bioavailability is present in T2D and the
MS [27]. During IR injury, iNOS has a beneficial role in
normal myocardium since iNOS knock-out non-diabetic
mice show a larger infarct size versus WT-controls [28].
The small magnitude of increase in iNOS levels in this
situation is important, because the up regulation of iNOS
has a pronounced dose-dependent effect: beneficial at
low levels but toxic at high levels [1,26]. In diabeticmyocardium, basal iNOS-levels are 3 times higher than in
non-diabetic myocardium [29]. Furthermore, the increase
of iNOS-levels in ischemic areas after IR injury is 2.6 times
larger than in the ischemic areas of non-diabetic myo-
cardium [29]. The detrimental role of these high iNOS-
levels during IR injury in diabetic myocardium was
confirmed in another study [28], in which iNOS knock-out
diabetic mice showed a smaller infarct size and reduced
caspase-3 activity versus control diabetic mice. This might
explain the increased sensitivity of our diabetic mice to IR
injury. In the delayed preconditioning pathway, iNOS has a
critical beneficial role [1]. Targeted deletion of the iNOS-
gene abrogates delayed preconditioning, suggesting that
iNOS is a common effector of cardioprotection [26]. Since
basal iNOS levels are higher, it is conceivable that diabetic
mice have a disturbed threshold or are even already in a
permanent maximally protected or preconditioned state.
Fifth, delayed preconditioning is regulated through an
up regulation of several other cardioprotective proteins
[1]. Previous studies focused mainly on the gene expres-
sion profile after delayed preconditioning in healthy
subjects [30] and the effect of diabetes or the metabolic
syndrome on this has never been investigated.
Finally, although a plethora of mechanisms are involved
in preconditioning, it is widely accepted that all these
mechanisms converge at the inhibition of the mitochon-
drial permeability transition pore (mPTP) opening at early
reperfusion [31]. Inhibiting mPTP opening will prevent
the cardiomyocytes to undergo cellular necrosis and apop-
tosis. No data are available about mPTP-inhibition in our
mouse models of T2D and the MS.
In an attempt to restore delayed preconditioning in
ob/ob and DKO mice, therapeutic strategies were in-
vestigated. After food restriction or ACE-I, hypoxic pre-
conditioning reduced infarct size and preserved PRSW
up to the level without ischemia in both ob/ob and
DKO. Furthermore, ACE-I restored the proportional ef-
fect of preconditioning on infarct limitation and con-
tractility improvement to the WT-level. Comparable
with our previous study [21], we found that diet or
ACE-I without preconditioning did not reduce the im-
pact of IR injury in these mice models, in contrast with
the regained protection by delayed preconditioning po-
tential in this study. The regained preconditioning po-
tential is thus independent from the direct effects of
ACE-I on IR injury. A possible explanation is that food
restriction and ACE-I are not capable to influence insu-
lin levels, glycemia, cholesterol, ROS, eNOS and iNOS
sufficiently to see an effect on IR injury without previous
preconditioning. Nevertheless, these parameters might
have been restored sufficiently to induce again a thresh-
old for delayed preconditioning.
It is already shown that food restriction reduces insu-
lin levels and ACE-I improves insulin sensitivity [14,19].
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mice and food restriction lowers cholesterol levels in ob/
ob mice [21]. This can have lowered the threshold to
delayed preconditioning since insulin has a precon-
ditioning effect [5,25], and hyperglycemia and hyperchol-
esterolemia are key player in the induction of atypical
isoforms of protein-kinase C [24], which is crucial in the
delayed preconditioning pathway [1]. In the aging heart,
an impaired protein-kinase C translocation is one of the
reasons responsible for the impaired preconditioning po-
tential [32].
Food restriction partially restores classical precon-
ditioning in senescent animals, but in combination with
exercise, this restoration becomes complete. A restored
norepinephrine release was suggested as the underlying
mechanism [32]. Furthermore, food restriction induces up-
regulation of eNOS in DKO mice [14]. ACE-I is capable to
block the degradation of bradykinin into inactive peptides
and to increase eNOS-levels [15,16,19,33]. eNOS is a trig-
ger in the delayed preconditioning pathway [1], which
might explain the regained preconditioning potential.
Food restriction prevents ROS production [34] and also
ACE-I has well known anti-oxidative activity [15,16,19].
Since an increase in ROS formation is an important trig-
ger of delayed preconditioning [1], it is possible that these
treatments reduce the increased baseline ROS-level in dia-
betic myocardium and restore the threshold for delayed
preconditioning [1].
Another possible explanation why the treatments in-
duced cardioprotection after preconditioning but did not
have a direct effect during IR injury, is the different role
and levels of iNOS in both pathways. As described earl-
ier, basal iNOS-levels are higher and the increase of
iNOS-levels after IR injury is larger than in non-diabetic
myocardium [29] with a deleterious role in diabetic
myocardium during IR injury [28]. In contrast with this,
a small increase in iNOS-levels is critical to induce its
effects as common end-effector in the delayed precon-
ditioning pathway [1]. No studies were conducted to
study the effect of food restriction on iNOS-levels in
myocardium, but it was shown in a normotensive rat
model that ACE-I reduces iNOS-levels with 24% [33]. It
is tempting to speculate that ACE-I did not reduce
iNOS-levels sufficiently to reduce its toxic high-dose
level during IR injury but enough to restore the thresh-
old to induce delayed precondition (by a small iNOS in-
crease). Further investigations need to be performed to
elucidate the role of these underlying mechanisms.
Conclusion
Hypoxic preconditioning induces a strong protection in
WT and a partial protection in ob/ob mice. The pre-
conditioning potential is lost in DKO. Twelve weeks of
food restriction or ACE-I restores the preconditioningpotential in DKO and improves it in ob/ob. After
preconditioning, PRSW is preserved to the level without
ischemia, after 12 weeks food restriction or ACE-I. As
previously shown, food restriction and ACE-I did not
protect the diabetic myocardium against IR injury. The
regained preconditioning potential appears to be inde-
pendent from the direct effects of food restriction ACE-I
on IR injury.
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